Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 July-August;177(7-8) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 July-August;177(7-8):343-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 July-August;177(7-8):343-7

DOI: 10.23736/S0393-3660.17.03727-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

DIFAPROST® data collection

Giuseppe R. TECCI 1, Alida AGOSTINI 2

1 Private Practitioner, Specialist in Urology, Milan, Italy; 2 Specialist in Biology, Cerasolo di Rimini, Rimini, Italy


PDF


BACKGROUND: Patients with prostatitis report common symptoms, characterized by perineal heaviness sensation, pain in the pubic area, occasional strangury, frequent urination and also urinary urgency. Many of the patients complain of nocturia, too. All these symptoms affect their quality of life. This work is based on the data collection derived from non homogeneous case reports of patients with mild and/or subacute prostatitis treated with DIFAPROST® with different follow-up periods.
METHODS: Data from 50 patients aged 18 to 75 years with mild and/or subacute prostatitis were collected. They have been recommended to undergo hydropinic therapy and follow a controlled diet, and were treated with DIFAPROST®, one tablet per day. The collected data were divided into 3 groups, based on the duration of the treatment.
RESULTS: After the first 30 days of treatment with DIFAPROST® all patients reported an improvement of the symptoms. In the majority of the patients also a significant improvement in urodynamic parameters was observed, in particular in T100 and in the voiding time between 5% and 95% of Vcomp. The group of patients treated for two months revealed also an improvement of the urination symptoms, reporting moreover no perineal and pubic heaviness sensation, no urinary urgency and a longer time available from the perception of urge to urinate until voiding. The group of patients treated for three months also confirms an improvement trend of urodynamic parameters.
CONCLUSIONS: Due to a synergic action of DIFAPROST® components, the symptoms of male urinary system dysfunction, caused by inflammation of the prostate gland, were improved since the first treatment month, reducing the times from short to very short. The treatment efficacy increases and becomes more pronounced over time. In addition to these beneficial results, PSA values were also positively influenced by the treatment, remaining low. The improvement of the quality of life, the simplicity of the treatment’s regimen and the absence of side effects, have definitely contributed to DIFAPROST® long-term everyday consumption.


KEY WORDS: Prostatitis - Urodynamics - Dietary supplements

top of page